Navigation Links
Mayo collaboration finds source of breast drug side effect
Date:9/27/2010

ROCHESTER, Minn. -- Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear today in the online issue of Journal of Clinical Oncology.

"Many women stop taking aromatase inhibitors due to the accompanying joint pain," says James Ingle, M.D., Mayo Clinic oncologist and senior author of the study. "We used the latest genetic technology in a very large group of women and discovered totally new clues to the cause of the main reason women stop this potentially lifesaving drug. Our findings open the door to finding ways to identify women who will develop these side effects and treat those who do, thus allowing more women to take this therapy and decrease their chances of breast cancer recurrence." Aromatase inhibitors are most often used as adjuvant therapy for postmenopausal women with early stage breast cancer.

How the Research Was Conducted

The researchers -- including investigators from the United States, Canada and Japan -- conducted a genome-wide association study to identify gene variants called single nucleotide polymorphisms (SNPs) that are associated with musculoskeletal pain. They selected patients who were enrolled in a prospective clinical trial, MA27, conducted by the NCIC Clinical Trials Group in Canada in collaboration with the NCI-sponsored North American Breast Cancer Groups comparing two aromatase inhibitor drugs. Two controls were matched with each patient and each patient who was selected experienced arthritis-like side effects within the first two years of treatment, or had already dropped out of the trial because of the pain. Researchers studied 293 separate cases, comparing them to 585 controls.

They found four likely SNPs on chromosome 14
'/>"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Alexza and Biovail Form Collaboration to Develop and Commercialize AZ-004 (Staccato(R) Loxapine) in North America
2. Web Content Management Enables Government Transparency, Participation, and Collaboration Online
3. MedPage Today(R) and Milwaukee Journal Sentinel Develop Journalism Content Collaboration for Enterprise Medical Reporting
4. NIH-FDA Joint Briefing on Regulatory Science Collaboration
5. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
6. Carefx Delivers Expert Insights on Health Data Sharing, Collaboration, Quality and Meaningful Use
7. Improved doctor-pharmacist collaboration needed: study
8. Tackling cardiovascular disease surge worldwide requires collaboration
9. French-Based Non-Profit AIDES is Starting a New Collaboration With Goodby, Silverstein & Partners
10. European collaboration seeks to create World Wide Web for robots
11. Johns Hopkins School of Medicine enters collaboration with New York Stem Cell Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... a new study done from the heights of Mount ... increases if you ascend to great heights. They ... high blood pressure was ineffective once climbers reached above ... 27 in the European Heart Journal , could ... level who have sleep apnea, in which a blocked ...
(Date:8/27/2014)... 2014 BESLER Consulting , a ... for hospitals, is pleased to announce that it has ... America’s Fastest-Growing Companies. The list represents the most comprehensive ... entrepreneurs. , "It's been an exciting year for ... in this year's Inc. 5000 list,” said Jonathan Besler, ...
(Date:8/27/2014)... The American Brain Tumor Association ... Basic Research Fellowships and 2014-2015 Discovery Grant Awards. Through ... seeding the field with talented, bright young investigators who ... causes, effects, diagnosis and treatment of brain tumors. This ... on the potential to advance the understanding and treatment ...
(Date:8/27/2014)... drug designed to help regulate the blood,s iron supply shows ... according to results from the first human study ... , the Journal of the American Society of ... red blood cells are in short supply or do not ... not get enough oxygen, since there are fewer red blood ...
(Date:8/27/2014)... A new analysis of clinical trial participation in the ... has found participants are not representative of the larger ... College Hospital cardiologist Dr. Jay Udell. The study authors ... to the wider population, and suggest the use of ... trial participation. , "We know that clinical trials can ...
Breaking Medicine News(10 mins):Health News:Everest Study Finds High Altitude Affects Blood Pressure 2Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Drug represents first potential treatment for common anemia 2Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2
... a combination of treatments tailor-made to their specific needs to ... immune response to cancer vaccines, because like the rest of ... efficient as we get older. Dr. Joseph Lustgarten, from the ... effects of aging on the immune system and strategies used ...
... are justified, say hearing loss experts who urge prevention , ... typically long -- and get longer when their children become ... about hearing loss. , Parents, in fact, worry more about ... health-related issues, including ear infections, sleep problems and asthma, according ...
... Greater Surface Disinfection to Combat Bad Hygiene , ARLINGTON, Va., ... standing in the lunch line? Or sneeze loudly into the ... (96 percent) have seen you do things like this -- and ... , Even with heightened concerns during this year,s flu season, ...
... , ... on the forefront of adopting social media outlets for physician recruitment , ... Alpharetta, GA (Vocus) October 8, 2009 -- "Jackson ... aspects of physician recruitment and other company functions," says company president, Sandra Garrett., , , ...
... ... malignancy after using a new treatment offered by NeoPlas Innovation. , ... Nashville, Tenn. (PRWEB) October 7, 2009 -- A patient ... after using a new treatment offered by NeoPlas Innovation . All evidence of disease ...
... Bipartisan Policy Center,s Health Care Report Urge Joint Leadership on ... is a statement released by Bipartisan Policy Center Founders and ... Bob Dole: , "After 14 months of work, on June ... It was the culmination of months of work as advisors ...
Cached Medicine News:Health News:Elderly immune system needs a boost 2Health News:As Teens Plug In, Parents Fret 2Health News:As Teens Plug In, Parents Fret 3Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 2Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 3Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 2Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 3Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 4Health News:Jackson & Coker Investigates the Impact of Social Media on Hospitals and Physicians 5Health News:Inoperable Colon Cancer Resolved After Four Months of New Treatment 2Health News:Inoperable Colon Cancer Resolved After Four Months of New Treatment 3
(Date:8/27/2014)... Aug. 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... of pharmaceutical development, clinical trial manufacturing, and advanced analytical ... that it will participate at the upcoming Rodman & ... be held in New York . ... on September 9, 2014 at the New York Palace ...
(Date:8/27/2014)... NORWALK, Conn. , Aug. 27, 2014  UBM ... , a leading online community for medical imaging professionals, ... Association for Medical Imaging Management,s 2014 Annual Meeting ... the conference coverage: , 11 Principles ... management can lead to greater profitability. , ...
(Date:8/27/2014)... DIEGO , Aug. 27, 2014 Ambit Biosciences (Nasdaq: ... and development of drugs targeting unmet needs in oncology, autoimmune ... Baird 2014 Health Care Conference to be held at The ... on September 3-4, 2014. Alan ... Company and its lead drug candidate, quizartinib, at 1:10 p.m. ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Ambit Announces Participation At Baird 2014 Health Care Conference 2
... Oramed Pharmaceuticals, Inc.,(OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... to present at the 8th National Life,Science & Technology ... by Mr. Nadav Kidron, President and CEO of Oramed,on ... p.m. (local time),at the David Intercontinental Hotel in Tel-Aviv, ...
... Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite ... , COPENHAGEN, June 9 A new analysis ... moderately to severely active rheumatoid arthritis (RA) who ... agents and received subcutaneous injections of SIMPONI(TM) (golimumab) ...
Cached Medicine Technology:Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 3New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 4New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 5New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 6New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 7New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 8New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 9New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 10
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: